A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Arcus Biosciences, Inc.
Ohio State University Comprehensive Cancer Center
TG Therapeutics, Inc.
Mayo Clinic
Roswell Park Cancer Institute
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)